SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.

@article{BenJosef2015SWOGSA,
  title={SWOG S0809: A Phase II Intergroup Trial of Adjuvant Capecitabine and Gemcitabine Followed by Radiotherapy and Concurrent Capecitabine in Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma.},
  author={Edgar Ben-Josef and Katherine Adams Guthrie and Anthony B El-Khoueiry and Christopher L . Corless and Mark M. Zalupski and Andrew M. Lowy and Charles R. Thomas and Steven Robert Alberts and Laura Ann Dawson and Kenneth Craig Micetich and Melanie Byrne Thomas and Abby B. Siegel and Charles David Blanke},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2015},
  volume={33 24},
  pages={2617-22}
}
PURPOSE The role of postoperative therapy in extrahepatic cholangiocarcinoma (EHCC) or gallbladder carcinoma (GBCA) is unknown. S0809 was designed to estimate 2-year survival (overall and after R0 or R1 resection), pattern of relapse, and toxicity in patients treated with this adjuvant regimen. PATIENTS AND METHODS Eligibility criteria included diagnosis of EHCC or GBCA after radical resection, stage pT2-4 or N+ or positive resection margins, M0, and performance status 0 to 1. Patients… CONTINUE READING